JP5211073B2 - 子宮内膜症の治療用の薬剤 - Google Patents
子宮内膜症の治療用の薬剤 Download PDFInfo
- Publication number
- JP5211073B2 JP5211073B2 JP2009547780A JP2009547780A JP5211073B2 JP 5211073 B2 JP5211073 B2 JP 5211073B2 JP 2009547780 A JP2009547780 A JP 2009547780A JP 2009547780 A JP2009547780 A JP 2009547780A JP 5211073 B2 JP5211073 B2 JP 5211073B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- endometriosis
- treatment
- cabergoline
- dopamine agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000009273 Endometriosis Diseases 0.000 title claims description 50
- 238000011282 treatment Methods 0.000 title claims description 38
- 239000003814 drug Substances 0.000 title description 5
- 229940079593 drug Drugs 0.000 title description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 67
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 44
- 229960004596 cabergoline Drugs 0.000 claims description 43
- 230000002357 endometrial effect Effects 0.000 claims description 36
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 27
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 26
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 26
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 24
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims description 17
- GDFGTRDCCWFXTG-SCTDSRPQSA-N (3r,4ar,10as)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline Chemical compound C1=CC=C2C[C@@H]3N(CCC)C[C@H](NS(=O)(=O)N(CC)CC)C[C@H]3CC2=C1O GDFGTRDCCWFXTG-SCTDSRPQSA-N 0.000 claims description 12
- 229960000924 quinagolide Drugs 0.000 claims description 12
- 210000004907 gland Anatomy 0.000 claims description 11
- 108010029741 Notch4 Receptor Proteins 0.000 claims description 8
- 102000001753 Notch4 Receptor Human genes 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 238000002651 drug therapy Methods 0.000 claims description 6
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 210000004204 blood vessel Anatomy 0.000 description 25
- 229940052760 dopamine agonists Drugs 0.000 description 25
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 21
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 230000006378 damage Effects 0.000 description 20
- 208000014674 injury Diseases 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 16
- 230000033115 angiogenesis Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 108010047303 von Willebrand Factor Proteins 0.000 description 12
- 102100036537 von Willebrand factor Human genes 0.000 description 12
- 229960001134 von willebrand factor Drugs 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000004696 endometrium Anatomy 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 description 5
- 102000052547 Wnt-1 Human genes 0.000 description 5
- 108700020987 Wnt-1 Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000001772 anti-angiogenic effect Effects 0.000 description 5
- 229960002802 bromocriptine Drugs 0.000 description 5
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 4
- 208000000450 Pelvic Pain Diseases 0.000 description 4
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100034594 Angiopoietin-1 Human genes 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000003886 aromatase inhibitor Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 3
- 229960000766 danazol Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000013425 morphometry Methods 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000007998 vessel formation Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 description 2
- 101710107142 Dopamine receptor 2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 2
- 229960002140 medetomidine Drugs 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 206010065951 Retrograde menstruation Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 229940109449 antisedan Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229960003002 atipamezole Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 201000002595 endometriosis of ovary Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000001158 estrous effect Effects 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 208000030747 ovarian endometriosis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07250429.3 | 2007-02-01 | ||
| EP07250429A EP1952813A1 (en) | 2007-02-01 | 2007-02-01 | Medicament for the treatment of endometriosis |
| US94716507P | 2007-06-29 | 2007-06-29 | |
| US60/947,165 | 2007-06-29 | ||
| GB0712626.1 | 2007-06-29 | ||
| GB0712626A GB2450533A (en) | 2007-06-29 | 2007-06-29 | Treatment and prevention of endometriosis using dopamine agonists. |
| PCT/IB2008/001273 WO2008093247A2 (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010517992A JP2010517992A (ja) | 2010-05-27 |
| JP2010517992A5 JP2010517992A5 (enExample) | 2010-12-02 |
| JP5211073B2 true JP5211073B2 (ja) | 2013-06-12 |
Family
ID=39674574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009547780A Active JP5211073B2 (ja) | 2007-02-01 | 2008-02-01 | 子宮内膜症の治療用の薬剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8927568B2 (enExample) |
| EP (1) | EP2109449B1 (enExample) |
| JP (1) | JP5211073B2 (enExample) |
| AR (1) | AR065139A1 (enExample) |
| AT (1) | ATE516805T1 (enExample) |
| AU (1) | AU2008211633B2 (enExample) |
| BR (1) | BRPI0806944A2 (enExample) |
| CA (1) | CA2676910C (enExample) |
| DK (1) | DK2109449T3 (enExample) |
| IL (1) | IL200032A (enExample) |
| JO (1) | JO2730B1 (enExample) |
| MX (1) | MX2009008191A (enExample) |
| NZ (1) | NZ578569A (enExample) |
| PL (1) | PL2109449T3 (enExample) |
| PT (1) | PT2109449E (enExample) |
| RU (1) | RU2423146C2 (enExample) |
| SA (1) | SA08290041B1 (enExample) |
| SI (1) | SI2109449T1 (enExample) |
| TW (1) | TWI411436B (enExample) |
| WO (1) | WO2008093247A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010150098A2 (en) * | 2009-06-26 | 2010-12-29 | Ferring International Center Sa | Treatment of endometriosis |
| EP3017809A1 (en) | 2014-11-07 | 2016-05-11 | Ferring B.V. | Drug-device unit containing quinagolide |
| WO2017210117A1 (en) * | 2016-06-02 | 2017-12-07 | Board Of Trustees, Southern Illinois University | Treatment of endometriosis and niclosamide derivatives |
| JP6562332B2 (ja) * | 2017-05-30 | 2019-08-21 | 有限会社イムノ | 活性化ｔ細胞からのｉｌ−８産生を抑制するための組成物 |
| RU2732251C1 (ru) * | 2019-11-29 | 2020-09-14 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения наружного генитального эндометриоза |
| US20240361338A1 (en) | 2021-08-31 | 2024-10-31 | Ferring B.V. | Diagnosis and treatment of ectopic endometriosis |
| WO2024153752A1 (en) | 2023-01-20 | 2024-07-25 | Ferring B.V. | Stereoselective synthesis of intermediates and synthesis of quinagolids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0208417A3 (en) * | 1985-06-12 | 1989-09-06 | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu | Use of 1-(8-alpha-ergolinyl)-3,3-diethyl urea derivatives in the treatment of endometritis |
| WO1993003752A1 (en) * | 1991-08-19 | 1993-03-04 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Decapeptide having dopamine stimulating activity |
| US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
| US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
| RU2273481C2 (ru) * | 2004-05-27 | 2006-04-10 | Варвара Анатольевна Волкова | Способ повышения эффективности лечения бесплодия, вызванного малыми формами внешнего генитального эндометриоза |
| WO2006117608A1 (en) * | 2005-04-29 | 2006-11-09 | Ferring International Center S.A. | Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist |
| WO2010150098A2 (en) * | 2009-06-26 | 2010-12-29 | Ferring International Center Sa | Treatment of endometriosis |
-
2008
- 2008-01-30 SA SA08290041A patent/SA08290041B1/ar unknown
- 2008-02-01 DK DK08751001.2T patent/DK2109449T3/da active
- 2008-02-01 MX MX2009008191A patent/MX2009008191A/es active IP Right Grant
- 2008-02-01 PT PT08751001T patent/PT2109449E/pt unknown
- 2008-02-01 NZ NZ578569A patent/NZ578569A/en not_active IP Right Cessation
- 2008-02-01 PL PL08751001T patent/PL2109449T3/pl unknown
- 2008-02-01 RU RU2009129252/15A patent/RU2423146C2/ru active
- 2008-02-01 WO PCT/IB2008/001273 patent/WO2008093247A2/en not_active Ceased
- 2008-02-01 AU AU2008211633A patent/AU2008211633B2/en not_active Ceased
- 2008-02-01 CA CA2676910A patent/CA2676910C/en active Active
- 2008-02-01 AR ARP080100431A patent/AR065139A1/es not_active Application Discontinuation
- 2008-02-01 SI SI200830385T patent/SI2109449T1/sl unknown
- 2008-02-01 EP EP08751001A patent/EP2109449B1/en active Active
- 2008-02-01 TW TW097103971A patent/TWI411436B/zh not_active IP Right Cessation
- 2008-02-01 AT AT08751001T patent/ATE516805T1/de active
- 2008-02-01 BR BRPI0806944-1A2A patent/BRPI0806944A2/pt not_active Application Discontinuation
- 2008-02-01 US US12/525,342 patent/US8927568B2/en active Active
- 2008-02-01 JP JP2009547780A patent/JP5211073B2/ja active Active
- 2008-02-02 JO JO200833A patent/JO2730B1/en active
-
2009
- 2009-07-23 IL IL200032A patent/IL200032A/en active IP Right Grant
-
2014
- 2014-11-17 US US14/543,478 patent/US9023862B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1134911A1 (en) | 2010-05-20 |
| IL200032A0 (en) | 2010-04-15 |
| SI2109449T1 (sl) | 2011-11-30 |
| WO2008093247A2 (en) | 2008-08-07 |
| RU2009129252A (ru) | 2011-03-10 |
| US20150073010A1 (en) | 2015-03-12 |
| RU2423146C2 (ru) | 2011-07-10 |
| AU2008211633B2 (en) | 2011-04-21 |
| US9023862B2 (en) | 2015-05-05 |
| SA08290041B1 (ar) | 2012-06-05 |
| IL200032A (en) | 2015-06-30 |
| EP2109449B1 (en) | 2011-07-20 |
| PL2109449T3 (pl) | 2011-12-30 |
| AR065139A1 (es) | 2009-05-20 |
| AU2008211633A1 (en) | 2008-08-07 |
| JO2730B1 (en) | 2013-09-15 |
| PT2109449E (pt) | 2011-11-02 |
| US8927568B2 (en) | 2015-01-06 |
| BRPI0806944A2 (pt) | 2014-05-06 |
| CA2676910A1 (en) | 2008-08-07 |
| WO2008093247A3 (en) | 2008-12-04 |
| TW200845989A (en) | 2008-12-01 |
| ATE516805T1 (de) | 2011-08-15 |
| US20100113499A1 (en) | 2010-05-06 |
| DK2109449T3 (da) | 2011-09-12 |
| EP2109449A2 (en) | 2009-10-21 |
| MX2009008191A (es) | 2009-08-12 |
| NZ578569A (en) | 2011-08-26 |
| CA2676910C (en) | 2012-01-03 |
| JP2010517992A (ja) | 2010-05-27 |
| TWI411436B (zh) | 2013-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5211073B2 (ja) | 子宮内膜症の治療用の薬剤 | |
| TWI445537B (zh) | 治療子宮類纖維瘤之方法 | |
| Harada et al. | SR-16234, a novel selective estrogen receptor modulator for pain symptoms with endometriosis: an open-label clinical trial | |
| CN100379455C (zh) | 预防或治疗子宫内膜异位症的药物 | |
| JP5968781B2 (ja) | 子宮内膜症の治療 | |
| KR20180035739A (ko) | 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체 | |
| EP1952813A1 (en) | Medicament for the treatment of endometriosis | |
| US20150099778A1 (en) | Therapeutic agent for lower urinary tract disease | |
| Jang et al. | Catamenial hemoptysis accompanied by subcutaneous endometriosis treated with combination therapy | |
| KR101160225B1 (ko) | 자궁 내막증 치료용 약제 | |
| GB2450533A (en) | Treatment and prevention of endometriosis using dopamine agonists. | |
| HK1134911B (en) | Medicament for the treatment of endometriosis | |
| CN100551379C (zh) | 积雪苷在制备预防或治疗肾脏纤维化的药物中的应用 | |
| JP2024162966A (ja) | 子宮内腔癒着および炎症性疾患の予防および／または治療におけるコラーゲンペプチドとアルギン酸ナトリウムとを組み合わせた混合物および／またはｎｌｒｐ３遺伝子ノックアウトおよび／またはｎｌｒｐ３阻害剤ｍｃｃ９５０の適用 | |
| WO2024208247A1 (zh) | 羧胺三唑在制备治疗肿瘤骨转移的药物中的用途 | |
| WO2023220396A1 (en) | Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor | |
| RU2428201C1 (ru) | Способ лечения начального рака эндометрия | |
| Narin et al. | Effects of natural progesterone on endometriosis in an experimental rat model: is it effective? | |
| CN116726016A (zh) | 尼达尼布在预防和治疗伤口增生性纤维化疾病的应用 | |
| Nakamura | Thrombospondin-1 Analog, ABT-898, Inhibits Endometriotic Lesion Vascularization Without Affecting Fertility or Pregnancy Outcomes in a Murine Model of Endometriosis | |
| JP2007529476A (ja) | ５−ｈｔ３受容体アンタゴニストを非消化管由来の有痛性腹部疾患の治療用医薬品の製造に用いる使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101012 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120904 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121129 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121213 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130212 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130225 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160301 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5211073 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |